A large, uniquely simple, randomised study to assess much more reliably the balance of benefits and risks of prolonging adjuvant tamoxifen treatment in early breast cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Jun 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 May 2020 Results evaluating HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients in the adjuvant tamoxifen, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
10 Sep 2014 Accrual to date is 110% according to United Kingdom Clinical Research Network record.
31 May 2012 Additional trial locations added as reported by United Kingdom Clinical Research Network.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com